Company Description
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer.
The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.
It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff.
The company was founded in 2009 and is headquartered in Westminster, Colorado.
| Country | United States |
| Founded | 2010 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Mary Szela |
Contact Details
Address: 6272 West 91st Avenue Westminster, Colorado 80031 United States | |
| Phone | 888 321 5212 |
| Website | trisaluslifesci.com |
Stock Details
| Ticker Symbol | TLSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001826667 |
| CUSIP Number | 89680M101 |
| ISIN Number | US89680M1018 |
| Employer ID | 85-3009869 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Mary T. Szela B.S.N., M.B.A. | Chief Executive Officer, President and Director |
| David B. Patience | Chief Financial Officer |
| Dr. Richard B. Marshak M.B.A., VMD | Chief Commercial Officer |
| Andrea Marasso | Vice President of Marketing |
| Jennifer L. Stevens J.D. | Chief Regulatory Officer |
| Jodi Devlin | Chief of Clinical Strategy and Operations |
| Dr. Bryan F. Cox Ph.D. | Chief of Research |
| Dr. Richard Marshall M.D. | Medical Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2026 | 8-K | Current Report |
| Mar 31, 2026 | ARS | Filing |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 424B5 | Filing |
| Feb 20, 2026 | 424B5 | Filing |
| Feb 20, 2026 | 8-K | Current Report |